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Abstract
Neuroﬁlament phosphoforms (Nf) are principal components of the
axoskeleton released during axonal injury. Cerebrospinal ﬂuid (CSF)
levels of Nf phosphoforms might be a useful surrogate marker for dis-
ability in multiple sclerosis (MS), aid in distinguishing clinical subtypes
and provide valuable prognostic information.
Thirty–four MS patients were included in a 3–year follow–up study
along with 318 non–inﬂammatory neurological controls. CSF levels
of 2 Nf heavy chain (NfH) phosphoforms (NfHSMI35 , NfHSMI34 ) were
quantiﬁed at baseline and 3–year follow–up using new ELISA tech-
niques. Levels of NfH phosphoforms, the degree of phosphorylation
(NfHSMI34 : NfHSMI35 ratio) and changes of NfH levels between base-
line and follow–up (NfH) were then related to the clinical phenotype
(relapsing remitting ‘RR’ or progressive ‘SP/PP’ disease), to 3 clinical
scales (Kurtzke’s EDSS, the ambulation index ‘AI’ and the 9 hole peg
test ‘9HPT’) and to progression of disability.
A signiﬁcantly higher proportion (59%) of patients with SP/PP dis-
ease experienced an increase in NfHSMI35 levels between baseline
and follow–up compared to those with RR disease (14%, p<0.05).
CSF NfHSMI34 levels were higher in SP/PP patients at baseline (11
pg/mL) compared to RR patients (9 pg/mL, p<0.05) and NfHSMI35 levels
were higher at follow-up (129 pg/mL) compared to levels below as-
say sensitivity (p<0.05). NfHSMI35 correlated with the EDSS (R=0.54,
p<0.01), the AI (R=0.42, p<0.05) and the 9HPT (R=0.59, p<0.01) at
follow–up.
The increase of NfH during the progressive phase of the disease
together with the correlation of NfHSMI35 with all clinical scales at
follow–up suggests that cumulative axonal loss is responsible for sus-
tained disability and that high NfHSMI35 levels are a poor prognostic
sign.Accumulated axonal damage in MS 4
Axonal pathology remains the “Achilles’ heel” of neurology. The new
insights form recent studies into the “axonal death cascade”1 in multiple
sclerosis (MS) are that a high number of transected axons are already
present in acute lesions2,3 (independent of demyelination4), in patients
with a short clinical course,2,5 and as a result of electrical activity in a
hostile micro–environment.6 Axonal loss results in atrophy of the spinal
cord,7 cerebellum8 and cortex,9 all of which correlate with disability.7–9 In
vivo quantiﬁcation of axonal damage is a key tool required for monitoring
and understanding axonal pathology in complex diseases such as MS.
Neuroﬁlaments (Nf) constitute a major component of the axoskeleton
and are promising candidates for quantiﬁcation of axonal damage because
axonal transection results in disintegration of the distal axon membrane
and Nf breakdown.?,10 Nf are released into the adjacent compartment, i.e.
the cerebrospinal ﬂuid (CSF) were they can be measured.11,12
This prospective study was stimulated by 3 questions:13,14 (1) Can clin-
ical subtypes of MS be distinguished on the basis of axonal damage (dis-
ease heterogeneity15)? (2) Does disability correlate with markers of axonal
pathology? And (3) Can we predict loss of function by using biomarkers
for axonal injury?
1 Methods
This study was approved by the local Ethics Committees. Written informed
consent was obtained from all patients.
Patients Thirty–four patients from a previously reported cohort16,17 with
clinically deﬁnite MS18 were followed up clinically after three years. A sec-
ond CSF sample was available in 29 patients at time of study. MS patientsAccumulated axonal damage in MS 5
were classiﬁed as having relapsing remitting (RR, n=11), or progressive
(SP/PP, n=23) disease.19 For the CSF analysis patients with primary (PP)
and secondary (SP) progressive disease were pooled because of small
numbers. However, a detailed subgroup analysis for the classiﬁcation of
RR, SP and PP MS patients at baseline as well as a subgroup analy-
sis of RR , SP (including those who converted from RR at baseline to
SP at follow–up) and PP at follow–up will also be presented. In nine of
the MS patients treatment with interferon beta (IFN) had been started
since the recruitment in 1996. The control group consisted of 318 patients
with other, non–inﬂammatory neurological diseases (OND) from the Na-
tional Hospital of Neurology and Neurosurgery. Restricted sample volume
meant not all assays could be performed on each sample and the numbers
available for each comparison are presented in Table 1.
Clinical assessment An Expanded Disability Status Scale score (EDSS)20
ranging from 0 (normal) to 10 (death due to multiple sclerosis), an ambula-
tion index (AI) ranging from 0 (no impairment) to 9 (restricted to wheelchair
without independent transfer) and a 9–hole PEG test (9HPT) measuring
upper limb motor function21 were performed on all patients within one week
of each lumbar puncture. Patients were classiﬁed as clinically advancing
if they worsened on the EDSS scale by at least 1 point for an EDSS < 5.5
or at least 0.5 point for an EDSS  5.5.
Assays Samples of CSF were obtained by routine lumbar puncture. Aliquots
of CSF were stored at -70◦C until assayed. Levels of NfH phosphoforms
were quantiﬁed using an in–house ELISA technique based on commer-
cially available antibodies.22 This ELISA has been optimised for the cap-Accumulated axonal damage in MS 6
ture antibody SMI35 which recognises a range of NfH phosphoforms (170
kDa, pI 6.2 to 210 kDa, pI 5.1). In contrast the capture antibody SMI34 only
recognises extensively phosphorylated NfH.23 Unfortunately non–phosphorylated
Nf are susceptible to proteases,23–25 of which the CSF is a rich source. For
this reason NfH=SMI32 was not measured in the present study and a ratio
of NfHSMI34 to NfHSMI35 was used to approximate the phosphorylation sta-
tus (see below). Albumin in CSF and serum was determined by standard
Laurell ‘rocket’ electro–immunoassay.
Data analysis All statistical analyses and graphs were done using SAS
software (version 8.2, SAS Institute, Inc., Cary, North Carolina, USA). Be-
cause of non–Gaussian distribution the median values and the 25–75 %
interquartile range (IQR) were shown. Independent variables were com-
pared using the non-parametric two-sample exact Wilcoxon rank-sum test.
If signiﬁcance was based on small numbers the results were checked by
the one–tailed Fisher’s exact test. The linear relationship between contin-
uous variables was evaluated using the Spearman correlation coefﬁcient.
Multiple correlations were corrected using the Bonferroni method. Linear
regression analysis was performed using the least–squares method.
The change of NfH levels between baseline and follow–up was ex-
pressed as the difference: NfH = NfH follow−up   NfH baseline A positive
number indicated an increase in the NfH follow–up levels. Because the in-
terassay CV for NfH is 10.6%, only an increase of at least 11% was consid-
ered for further statistical analysis.22 The phosphoform ratio is an estimate
of the degree of phosphorylation and was expressed as a cross–sectional
measure: RATIO =
NfH SMI34
NfH SMI35  10. A decrease of the ratio indicates an
overall reduction in the level of phosphorylation. Values with zero denomi-Accumulated axonal damage in MS 7
nator (or NfH at baseline and follow–up below assay sensitivity) could not
be calculated and were excluded from this analysis.
2 Results
The demographic data at baseline are shown in Table 1. As expected at
baseline EDSS, AI and 9HPT were worse in patients with SP/PP disease
than in those with RR disease. The CSF levels of NfHSMI35
baseline were higher
in the OND than in the MS patients (p<0.01, Table 2 A). The CSF levels
of NfH
SMI34
baseline were similar in OND subjects compared to MS patients. No
correlations were found between any Nf phosphoform or their ratio with ei-
ther age, disease duration, time from last relapse, relapse frequency or the
CSFalbumin
Serumalbumin ratio (data not shown). The shortest relapse free time was 3
month at baseline in 2 patients. At follow up 1 patient with SP/PP MS suf-
fered from a superimposed relapse 2 weeks prior to CSF sampling. There
was no correlation with time from relapse in either SP/PP MS patients or
RR MS patients for either sampling point.
Axonal damage accumulates in SP/PP disease A signiﬁcant increase
in NfHSMI35 from baseline to follow–up was observed in a higher proportion
of patients with SP/PP MS (13/22, 59%, Figure 1) when compared to RR
patients (1/7, 14%, p<0.05). At follow–up median CSF NfHSMI35 levels
were higher in patients with SP/PP disease compared to patients with RR
disease (Table 2 B, p<0.05).
An increase of NfHSMI34 was observed in a similar proportion of pa-
tients with RR (5/7, 71%) and with SP disease (15/22, 68%). The CSF
NfH
SMI34
baseline was higher in patients with SP/PP than with RR disease (Ta-
ble 2 A, p<0.05). The proportion of RR patients with an increase inAccumulated axonal damage in MS 8
NfHSMI34 (71%) was higher than the proportion with an increase in NfHSMI35 (14%,
p<0.05). The
NfH SMI34
NfH SMI35 ratio decreased in 6/7 (86%) of patients with RR and
12/22 (55%) with SP disease. Neither of these comparisons reached sta-
tistical signiﬁcance.
Axonal injury correlates with disability NfHSMI35 levels correlated with
all clinical scales at follow–up (Figure 2 A,B,C). The correlation was strongest
for for the 9HPT (R=0.59, p=0.001), followed by the EDSS (R=0.54, p<0.01)
and the AI (R=0.42, p<0.05). The correlation with the AI was lost after
Bonferroni correction. One outlier was observed for the 9HPT (Figure 2
C). Exclusion of this outlier did not change the signiﬁcance of the anal-
ysis (R=0.55, p<0.01). The NfH phosphoform ratio correlated with the
EDSS (R=0.52, p<0.05) at follow–up, but this signiﬁcance was lost after
the Bonferroni correction. No signiﬁcant correlation was found for any NfH
phosphoform with the change of EDSS, AI or 9HPT over the 3–year pe-
riod (data not shown) At baseline no such correlations were demonstrated
after Bonferroni correction for any of the NfH phosphoforms or their ratio.
Axonal injury and prognosis There was a tendency for higher median
CSF NfHSMI35 levels in MS patients who progressed on the EDSS scale
within 3–years (107 pg/mL) when compared to those who remained stable
(38 pg/mL). However this difference did not reach statistical signiﬁcance for
either the total MS cohort or the clinical subtypes (Table 3). However, using
an arbitrary cut–off level of 20 pg/mL (assay sensitivity) on the baseline
cohort, the positive predictive value of high NfHSMI35 levels for predicting
progression on the EDSS scale within 3–years was 100% for RR MS and
20% for SP/PP MS patients with a speciﬁcity of 100% and 20% and aAccumulated axonal damage in MS 9
sensitivity of 87.5% and 75%, respectively.
Three RR patients converted to SP disease in the 3–year observa-
tion period. Patients with RR disease who converted to SP disease had
higher median CSF NfHSMI35 levels (123 pg/mL) when compared to non–
converting RR patients (49 pg/mL) at baseline. Again this difference did
not reach statistical signiﬁcance.
Patients treated with IFN had a lower median EDSS on baseline (2.0
versus 5.5; p<0.05), follow–up (4.0 versus 4.5; p<0.05) and were less pro-
gressive (improvement by a median of 1.5 points on the EDSS compared
to no change; p<0.05) compared to untreated patients. IFN treated pa-
tients had lower CSF NfH
SMI34
baseline levels (7 pg/mL) compared to non–treated
patients (11 pg/mL, p<0.01). No such differences were found for NfHSMI35
baseline or
the NfH phosphoform ratio.
Subgroup analysis Because there are differences in pathogenesis be-
tween SP and PP MS, particularly with reference to the degree of inﬂam-
mation, CSF levels of NfHSMI35 , NfHSMI34 and the ratio were also examined
for all individual subgroups.
At baseline there was a signiﬁcant difference between these groups
for NfHSMI34 (F(2,26)=5.00, p<0.05). The post–hoc analysis revealed that
CSF NfHSMI34 levels were higher in patients with PP disease (mean=26.6
pg/mL) compared to patients with SP (mean=10.19 pg/mL, p<0.01) or RR
disease (mean=9.30 pg/mL, p<0.01).
At follow–up no such difference was found, probably due to small num-
bers and therefore no post–hoc analysis was performed.Accumulated axonal damage in MS 10
3 Discussion
This study (1) provided evidence that accumulation of axonal damage as
estimated by serial CSF NfHSMI35 levels predominated in SP/PP MS, (2)
reveals a correlation of CSF NfHSMI35 levels with the degree of disability
on 3 clinical scales (EDSS, AI, 9HPT) and (3) failed to demonstrate that
CSF NfH phosphoforms might predict the development of new disability in
patients with MS. We interpret these ﬁndings on basis of the epidemiolog-
ically supported hypothesis that axonal damage is a gradual cumulative
process during the disease course26,27 and that loss of neurological func-
tion is a direct consequence of axonal injury.2,13,14
Firstly, NfHSMI35 levels increased from baseline to the 3–year follow up
sampling in about half of the MS patients. A signiﬁcantly higher propor-
tion of these patients had SP/PP than RR disease. Additionally the mean
NfHSMI35
follow−up levels were signiﬁcantly higher in SP/PP rather than in RR dis-
ease. This marked increase of NfH
SMI34
baseline suggests that NfH phosphory-
lation may increase with disease duration. This interpretation contrasts
with the consistent immunocytochemical observation that injured and de-
myelinated axons stain for non–phosphorylated NfH (NfH=SMI32).2,28–31
However, none of these studies presented quantitative data comparing the
amount of axons staining for phosphorylated versus non–phosphorylated
NfH. A further complicating factor is that proteolytic enzyme activity is a
prominent feature of the MS plaque32,33 and potentially affects the lev-
els particular of non–phosphorylated NfH which is susceptible to proteoly-
sis.23–25 To address this question we are currently analysing the quantita-
tive distribution of NfH phosphoforms (NfHSMI32 , NfHSMI34 and NfHSMI35 )
in microdissected brain tissue homogenate from a previously publishedAccumulated axonal damage in MS 11
cohort.16,34,35 An increase of NfH phosphorylation supports our ﬁnding
and can be explained by targeted phosphorylation of the KSP repeats of
the NfH and NfM tail domains by ERK1/2.36 Fibrin upregulates ERK1/237
and has shown to be deposited on injured axons.34,35,38 Additionally the
MAP kinases SAPKs and ERK1/2 are activated by glutamate39–43 which
in turn leads to Ca–inﬂux, slowing of axonal Nf transport and increased
Nf phosphorylation.44,45 Glutamate toxicity is an important pathological
feature in MS, metabotropic glutamate receptor group I alpha is upregu-
lated on axons in multiple sclerosis28 and experimental treatment with the
AMPA/kainate antagonist NBQX reduces axonal damage in experimen-
tal autoimmune encephalomyelitis.29 The present CSF results are also be
consistent with the postmortem observation that axonal damage increases
with time in SP/PP MS patients,46 with additional support from brain imag-
ing47 and epidemiological studies.27
Secondly, a correlation between CSF NfHSMI35 and 3 clinical scales
was shown. This ﬁnding indirectly conﬁrms two previous reports on a dif-
ferent neuroﬁlament subunit (the 68 kDa light chain, NfL).11,12 In the study
of Lycke et al. CSF NfL correlated with the EDSS at baseline (R=0.27)
and follow–up (R=0.34) in RR MS patients.11 In the study by Semra et al.
CSF NfL correlated with the EDSS (R=0.41) in progressive MS patients.
However, no such correlations were found at baseline in either our original
study,17 the present follow–up cohort or a recent study on RR MS and SP
MS patients.48 Because clinically some of our SP/PP patients improved
a degree of disability at baseline, it is likely that conduction block and de-
myelination which are, in contrast to axonal loss, reversible, contributed to
the deﬁcit.
Thirdly, a tendency for higher median CSF NfHSMI35
baseline and NfH
SMI34
baseline levelsAccumulated axonal damage in MS 12
were observed in those MS patients who progressed clinically on the EDSS
scale. This was most marked for patients with RR disease and suggests
that axonal damage during the course of MS is a poor prognostic feature.
However, the study failed to show statistical difference. The high posi-
tive predictive value and sensitivity suggest that this might be due to small
sample size. It is important to note that axonal loss is not the dominant
pathological feature in MS compared to other neurological diseases.22,49
Nevertheless the demonstrated slow accumulation of axonal loss seems
a logical explanation for the development of sustained disability in the pro-
gressive course of the disease.
The interpretation of the present data needs to consider that the pa-
tient group is population based and numbers are small. Clinically there
was no signiﬁcant change in the EDSS of the SP/PP MS patients within
3 years. This represents a benign course compared to the more rapid
progression observed in other cohorts of patients selected from hospital
populations. Additionally the low median CSF NfHSMI35 levels in the RR
MS cohort at follow–up would suggest that these patients might have a
benign disease course. The results must be interpreted with caution and
will need to be cross–validated in other longitudinal studies with different
cohort of patients.
Taking all these observations together, the results of this study are
in accordance with the current concept of progressive axonal degener-
ation in MS which is based on evidence from animal,50,51 human post-
mortem,2,3,5,35,46,52 magnetic resonance spectroscopy,53 magnetic reso-
nance imaging7–9,54 and epidemiological studies.27,55
The results of this prospective 3–year study support the idea that CSF
NfH phosphoforms might be valuable surrogate markers which have theAccumulated axonal damage in MS 13
potential to be used as a new secondary outcome measures in MS treat-
ment trials.
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Note During the review process of this paper a seperate study on the
cerebrospinal neuroﬁlament phosphoforms (NfHSMI34 and NfHSMI35 ) has
been published by Ee Tuan Lim et al. “Cerebrospinal ﬂuid levels of brain
speciﬁc proteins in optic neuritis”. Multiple Sclerosis 2004;10:261–265.
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OND Multiple sclerosis
NfHSMI35 NfHSMI34 Ratio MS (all) SP/PP RR
Female:Male 155:116 61:58 32:28 15:19 11:12 4:7
Age 44.0 45.4 47.2 46.5 48.5 39.6
(years) (1–77.9) (34.9–52.9) (42.5–51.5) (42.5–51.5) (42.5–51.5) (34.9–47.7)
Disease dura-
tion
N/A N/A N/A 14.0 16.0 8.1
(years) (8.0–19.9) (11.8–21.8) (3.7–13.0)
Relapse–free
interval
N/A N/A N/A 38.0 83.0 8.0
(months) (8.0–96.0) (23.5–144.5) (3.0–38.0)
Number 271 119 60 34 23 11
Table 1: Baseline characteristics of the patients. The
median (IQR) are shown. Patients with SP/PP disease
had a longer disease duration (p<0.05) and relapse-
free interval (p<0.05).Accumulated axonal damage in MS 22
(A)
Clinical subgroup
Baseline CTRL MS (all) SP/PP RR
NfHSMI35 pg/mL 260 78 95 53
(0–3990) (80–610) (25–163) (11–139)
—— p<0.001 ——
NfHSMI34 pg/mL 10 9 11 7
(0–12000) (7–13) (7–14) (5–9)
——— p<0.05 ———
Ratio 1.52 1.5 1.7 1
(0.36–5.49) (0.6–5.4) (0.6–5.8) (0.42–3.5)
EDSS N/A 3.25 6.0 1.5
(2.0–6.5) (3.0–7.0) (1.0–2.0)
——— p<0.001 ———
AI N/A 2 6 1
(1–7) (2–8) (1–1)
——— p<0.01 ———
9HPT N/A 24.5 26.0 20.0
(20.5–28.5) (24.0–30.0) (18.0–22.0)
——— p<0.01 ———
Number 271/119 29 19 10
(B)
Clinical subgroup
Follow–Up CTRL MS (all) SP/PP RR
NfHSMI35 pg/mL N/A 113 129 0
(0–178) (0–209) (0–120)
——— p<0.05 ———
NfHSMI34 pg/mL N/A 50 30 51
(9–129) (10–114) (3–120)
Ratio N/A 3 3 5
(1–10.1) (1–10.1) (0–10)
 NfHSMI35 pg/mL N/A 4 82 -49
(-59–98) (-38–115) (-38–104)
 NfHSMI34 pg/mL N/A 37.0 22.0 51
(-1–123) (-3–95) (1–112)
EDSS N/A 4.5 5.5 3.0
(3.5–6.0) (4.0–6.5) (2.5–4.0)Accumulated axonal damage in MS 23
——— p<0.01 ———
AI N/A 2 4 1
(2–5) (2–7) (1–2)
——— p<0.01 ———
9HPT N/A 23.5 24.5 20.0
(20.0–28.5) (21.5–31.0) (18.0–21.0)
——— p<0.05 ———
Number — 29 19 10
Table 2: (A) Baseline CSF levels and ratio of NfH phos-
phoforms, EDSS, AI and 9HPT (median, IQR) in OND
and MS patients. (B) Follow–up CSF levels, ratio and
change over time (NfH), NfH phosphoforms, EDSS,
AI and 9HPT.Accumulated axonal damage in MS 24
MS (all) SP/PP RR
Stable Progressive Stable Progressive Stable Progressive
NfHSMI35 38 107 42 104 5 115
(pg/mL) (17–155) (49–163) (24–173) (78–173) (0–53) (43–165)
NfHSMI34 11 8 11 9 2 7.5
(pg/mL) (5–13) (5–14) (7.5–13.0) (5–16) (0–5) (6–11)
Ratio 3.2 1.0 3.2 1.1 2.5 0.9
(0.6–5.8) (0.4–3.5) (0.6–6.0) (0.5–1.7) (0.9–4.0) (0.4–3.5)
Number 19 15 16 7 3 8
Table 3: CSF levels and ratio of NfH phosphoforms
(median, IQR) for clinically progressive versus stable
patients at baseline.Accumulated axonal damage in MS 25
RR SP/PP
baseline follow–up baseline follow–up
RR SP/PP
baseline follow–up baseline follow–up
(A) (B)
Figure 1: (A) CSF NfHSMI35 levels in patients RR (open circles) and SP/PP
(diamonds) forms of MS. A signiﬁcantly higher proportion of SP/PP MS
patients (13/22) had increased CSF NfHSMI35 levels between baseline and
follow–up (straight lines) when compared to RR MS patients (1/7, p<0.05,
Fisher’s exact test). (B) CSF NfHSMI34 levels in patients RR (open circles)
and SP/PP (diamonds) forms of MS.Accumulated axonal damage in MS 26
(A) (B) (C)
Figure 2: Correlation between the CSF NfHSMI35 levels and (A) the EDSS,
(B) the AI and (C) the 9HPT (log transformed scale) at follow–up.